147 related articles for article (PubMed ID: 37060904)
1. Lysine long-chain fatty acylation regulates the TEAD transcription factor.
Noritsugu K; Suzuki T; Dodo K; Ohgane K; Ichikawa Y; Koike K; Morita S; Umehara T; Ogawa K; Sodeoka M; Dohmae N; Yoshida M; Ito A
Cell Rep; 2023 Apr; 42(4):112388. PubMed ID: 37060904
[TBL] [Abstract][Full Text] [Related]
2. Effect of the acylation of TEAD4 on its interaction with co-activators YAP and TAZ.
Mesrouze Y; Meyerhofer M; Bokhovchuk F; Fontana P; Zimmermann C; Martin T; Delaunay C; Izaac A; Kallen J; Schmelzle T; Erdmann D; Chène P
Protein Sci; 2017 Dec; 26(12):2399-2409. PubMed ID: 28960584
[TBL] [Abstract][Full Text] [Related]
3. The role of lysine palmitoylation/myristoylation in the function of the TEAD transcription factors.
Mesrouze Y; Aguilar G; Meyerhofer M; Bokhovchuk F; Zimmermann C; Fontana P; Vissières A; Voshol H; Erdmann D; Affolter M; Chène P
Sci Rep; 2022 Mar; 12(1):4984. PubMed ID: 35322151
[TBL] [Abstract][Full Text] [Related]
4. Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway.
Chan P; Han X; Zheng B; DeRan M; Yu J; Jarugumilli GK; Deng H; Pan D; Luo X; Wu X
Nat Chem Biol; 2016 Apr; 12(4):282-9. PubMed ID: 26900866
[TBL] [Abstract][Full Text] [Related]
5. Convergence of YAP/TAZ, TEAD and TP63 activity is associated with bronchial premalignant severity and progression.
Ning B; Tilston-Lunel AM; Simonetti J; Hicks-Berthet J; Matschulat A; Pfefferkorn R; Spira A; Edwards M; Mazzilli S; Lenburg ME; Beane JE; Varelas X
J Exp Clin Cancer Res; 2023 May; 42(1):116. PubMed ID: 37150829
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of TEAD transcription factors in cancer.
Pobbati AV; Kumar R; Rubin BP; Hong W
Trends Biochem Sci; 2023 May; 48(5):450-462. PubMed ID: 36709077
[TBL] [Abstract][Full Text] [Related]
7. Palmitoylation of TEAD Transcription Factors Is Required for Their Stability and Function in Hippo Pathway Signaling.
Noland CL; Gierke S; Schnier PD; Murray J; Sandoval WN; Sagolla M; Dey A; Hannoush RN; Fairbrother WJ; Cunningham CN
Structure; 2016 Jan; 24(1):179-186. PubMed ID: 26724994
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Design of Y-Shaped Covalent TEAD Inhibitors.
Lu W; Fan M; Ji W; Tse J; You I; Ficarro SB; Tavares I; Che J; Kim AY; Zhu X; Boghossian A; Rees MG; Ronan MM; Roth JA; Hinshaw SM; Nabet B; Corsello SM; Kwiatkowski N; Marto JA; Zhang T; Gray NS
J Med Chem; 2023 Apr; 66(7):4617-4632. PubMed ID: 36946421
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the Hippo Pathway Transcription Factor TEAD.
Lin KC; Park HW; Guan KL
Trends Biochem Sci; 2017 Nov; 42(11):862-872. PubMed ID: 28964625
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
[TBL] [Abstract][Full Text] [Related]
11. Discovering inhibitors of TEAD palmitate binding pocket through virtual screening and molecular dynamics simulation.
Li Y; Li Y; Ning C; Yue J; Zhang C; He X; Wang Y; Liu Z
Comput Biol Chem; 2022 Jun; 98():107648. PubMed ID: 35288361
[TBL] [Abstract][Full Text] [Related]
12. Cell contact and Nf2/Merlin-dependent regulation of TEAD palmitoylation and activity.
Kim NG; Gumbiner BM
Proc Natl Acad Sci U S A; 2019 May; 116(20):9877-9882. PubMed ID: 31043565
[TBL] [Abstract][Full Text] [Related]
13. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
14. Vestigial-like family member 3 (VGLL3), a cofactor for TEAD transcription factors, promotes cancer cell proliferation by activating the Hippo pathway.
Hori N; Okada K; Takakura Y; Takano H; Yamaguchi N; Yamaguchi N
J Biol Chem; 2020 Jun; 295(26):8798-8807. PubMed ID: 32385107
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of YAP/TAZ-TEAD activity induces cytotrophoblast differentiation into syncytiotrophoblast in human trophoblast.
Mizutani T; Orisaka M; Miyazaki Y; Morichika R; Uesaka M; Miyamoto K; Yoshida Y
Mol Hum Reprod; 2022 Sep; 28(10):. PubMed ID: 35993908
[TBL] [Abstract][Full Text] [Related]
16. Regulation of TEAD Transcription Factors in Cancer Biology.
Huh HD; Kim DH; Jeong HS; Park HW
Cells; 2019 Jun; 8(6):. PubMed ID: 31212916
[TBL] [Abstract][Full Text] [Related]
17. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
[TBL] [Abstract][Full Text] [Related]
18. Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling.
Fan M; Lu W; Che J; Kwiatkowski NP; Gao Y; Seo HS; Ficarro SB; Gokhale PC; Liu Y; Geffken EA; Lakhani J; Song K; Kuljanin M; Ji W; Jiang J; He Z; Tse J; Boghossian AS; Rees MG; Ronan MM; Roth JA; Mancias JD; Marto JA; Dhe-Paganon S; Zhang T; Gray NS
Elife; 2022 Oct; 11():. PubMed ID: 36300789
[TBL] [Abstract][Full Text] [Related]
19. Establishment of transgenic lines to monitor and manipulate Yap/Taz-Tead activity in zebrafish reveals both evolutionarily conserved and divergent functions of the Hippo pathway.
Miesfeld JB; Link BA
Mech Dev; 2014 Aug; 133():177-88. PubMed ID: 24560909
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a new class of reversible TEA domain transcription factor inhibitors with a novel binding mode.
Hu L; Sun Y; Liu S; Erb H; Singh A; Mao J; Luo X; Wu X
Elife; 2022 Nov; 11():. PubMed ID: 36398861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
